Item 2.02 Results of Operations and Financial Condition

As discussed below, in connection with its participation in the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California, Aprea Therapeutics, Inc. (the "Company") updated its corporate presentation to include disclosure that the Company had $130.1 million of cash and cash equivalents (unaudited) as of December 31, 2019.

Because the Company's consolidated financial statements for the year ended December 31, 2019 have not yet been finalized or audited, the preliminary statement of the Company's cash and cash equivalents as of December 31, 2019 in this Item 2.02 is subject to change, and the Company's actual cash and cash equivalents as of December 31, 2019 may differ materially from this preliminary estimate. Accordingly, you should not place undue reliance on this preliminary estimate.

Item 7.01 Regulation FD Disclosure

Beginning on January 13, 2020, the Company will participate in the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California. The Company has updated its corporate presentation that it intends to use in connection with its presentation on Tuesday January 14, 2020 at 3:30 p.m. Pacific Time and in meetings with investors. The updates primarily include updates on the Company's ongoing and planned clinical trials and disclosure regarding the Company's cash and cash equivalents as of December 31, 2019.

A copy of the Company's corporate presentation is attached hereto as Exhibit 99.1 and is hereby incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.






(d)    Exhibits.



Exhibit
 Number                   Description
  99.1       Aprea Therapeutics, Inc. Presentation




                                     - 2 -

© Edgar Online, source Glimpses